Cargando…
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
This study sought to determine whether the sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved heart failure (HF) outcomes in nondiabetic mice. The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial demonstrated that em...
Autores principales: | Byrne, Nikole J., Parajuli, Nirmal, Levasseur, Jody L., Boisvenue, Jamie, Beker, Donna L., Masson, Grant, Fedak, Paul W.M., Verma, Subodh, Dyck, Jason R.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034464/ https://www.ncbi.nlm.nih.gov/pubmed/30062155 http://dx.doi.org/10.1016/j.jacbts.2017.07.003 |
Ejemplares similares
-
Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018) -
The use of chromoendoscopy for surveillance of inflammatory bowel disease
por: Lichtenstein, Gary R., et al.
Publicado: (2018) -
Trade in wild animals: a disaster ignored
por: The Lancet Infectious Diseases
Publicado: (2003) -
A European CDC
por: The Lancet Infectious Diseases
Publicado: (2003) -
An appropriate response to SARS
por: The Lancet Infectious Diseases
Publicado: (2003)